Bladder Cancer

Papers
(The TQCC of Bladder Cancer is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives21
Association of CCL2/CCR2 gene polymorphisms and bladder cancer risk in a hispanic-rich US population19
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer18
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models12
Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract11
Patterns of care and associated social determinants of health in the definitive treatment of localized muscle-invasive bladder cancer patients11
Comparison of Robotic vs Open Cystectomy: A Systematic Review10
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort10
Computational pathology in bladder cancer: A scoping review9
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancer8
Standard vs extended lymphadenectomy for muscle invasive bladder cancer8
Clinical Trials Corner Issue 9(2)8
Urologists and Advanced Practice Providers Evaluating Hematuria8
Management of bladder cancer in kidney transplant recipients: A narrative review7
Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization6
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder6
Clinical trials corner issue 12(1)6
Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression6
A New Standard of Care for Bladder Cancer5
Expression of PD-1 and PD-L1 in BCG-treated NMIBC5
Clinical Trials Corner Issue 10(2)5
Analysis of sarcopenia indicators on survival prediction undergoing radical cystectomy4
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It4
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes4
Organoid models in bladder cancer: From bench to bedside?4
Proceedings of the first international NMIBC consensus classification meeting4
Y Chromosome Loss and Bladder Cancer3
Challenging Cases in Urothelial Cancer: Case 333
Commentary on Novitas LCD3
Challenging Cases in Urothelial Cancer: Case 263
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?3
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?3
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC3
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets3
0.14554405212402